Terauchi H, Tanitame A, Tada K, Nakamura K, Seto Y, Nishikawa Y
Discovery Research Laboratories, Dainippon Pharmaceutical Company, Ltd., Suita/Osaka, Japan.
J Med Chem. 1997 Jan 31;40(3):313-21. doi: 10.1021/jm9605593.
A new series of N-Substituted 2-(benzhydryl- and benzylsulfinyl)nicotinamides 7 and 8 were synthesized. Upon acid activation in the acidic environment of the parietal cell, these compounds are converted into their active forms, 2,3-dihydro-3-oxoisothiazolo[5,4-b]pyridines 5, which inhibit gastric H+/K(+)-ATPase. Inhibitory activities against [14C]aminopyrine accumulation stimulated by dibutyryl cAMP in isolated rabbit parietal cells in vitro and histamine-induced gastric acid secretion in pylorus-ligated rats by intraduodenal administration in vivo were evaluated, and the structure-activity relationships were examined. Among the compounds synthesized, 2-[(2,4-dimethoxybenzyl)sulfinyl]-N-(4-pyridyl)nicotinamide (8b) showed potent inhibitory activities in vitro and in vivo equivalent to those of omeprazole, a typical H+/K(+)-ATPase inhibitor. Moreover, 8b was much more stable at neutral and weakly acidic pH than omeprazole, lansoprazole, and pantoprazole. Compound 8b is considered to be a promising agent for treating acid-related gastrointestinal disorders.
合成了一系列新的N-取代的2-(二苯甲基-和苄基亚磺酰基)烟酰胺7和8。在壁细胞的酸性环境中经酸活化后,这些化合物转化为其活性形式2,3-二氢-3-氧代异噻唑并[5,4-b]吡啶5,其可抑制胃H⁺/K⁺-ATP酶。评估了它们对体外分离的兔壁细胞中由二丁酰环磷腺苷刺激的[¹⁴C]氨基比林蓄积以及体内十二指肠内给药对幽门结扎大鼠组胺诱导的胃酸分泌的抑制活性,并研究了构效关系。在所合成的化合物中,2-[(2,4-二甲氧基苄基)亚磺酰基]-N-(4-吡啶基)烟酰胺(8b)在体外和体内均表现出与典型的H⁺/K⁺-ATP酶抑制剂奥美拉唑相当的强效抑制活性。此外,8b在中性和弱酸性pH下比奥美拉唑、兰索拉唑和泮托拉唑稳定得多。化合物8b被认为是治疗酸相关性胃肠疾病的有前景的药物。